ZHAO Junfang, LI Guizhen, CHEN Xuewen. Determinations of OX40 mRNA,OX40L mRNA and anti-C1q antibody and their diagnosis performance in peripheral blood of patients with lupus nephritis[J]. Laboratory Medicine, 2016, 31(10): 889-893.
HOCHBERG MC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum,1997,40(9):1725.
[3]
MESQUITA D JR,CRUVINEL WM,ARAUJO JA,et al.Imbalanced expression of functional surface molecules in regulatory and effector T cells in systemic lupus erythematosus[J]. Braz J Med Biol Res,2014,47(8):662-669.
[4]
DOLFF S,QUANDT D,WILDE B,et al.Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus[J]. Arthritis Res Ther,2010,12(4):R150.
[5]
FARRES MN,AL-ZIFZAF DS,ALY AA,et al.OX40/OX40L in systemic lupus erythematosus:association with disease activity and lupus nephritis[J]. Ann Saudi Med,2011,31(1):29-34.
[6]
SONG J,SO T,CROFT M.Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival[J]. J Immunol,2008,180(11):7240-7248.
[7]
ZHOU YB,YE RG,LI YJ,et al.Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis[J]. Rheumatol Int,2009,29(4):417-425.
[8]
TRENDELENBURG M.Anti-C1q antibodies as a diagnostic marker of proliferative lupus nephritis:comment on the article by Katsumata et al[J]. Arthritis Rheum,2012,64(1):324-325.